PuSH - Publication Server of Helmholtz Zentrum München: Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Hosseini, A.* ; Dhall, A.* ; Ikonen, N.* ; Sikora, N.* ; Nguyen, S.* ; Shen, Y.* ; Amaral, M.L.J.* ; Jiao, A.L.* ; Wallner, F.* ; Sergeev, P.* ; Lim, Y.H.* ; Yang, Y.* ; Vick, B. ; Kawabata, K.C.* ; Melnick, A.* ; Vyas, P.* ; Ren, B.* ; Jeremias, I. ; Psaila, B.* ; Heckman, C.A.* ; Blanco, M.A.* ; Shi, Y.*

Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.

Nature, 40 (2025)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Hybrid

Abstract
Metrics
Extra information

Impaired differentiation is a hallmark of myeloid malignancies^1,2. Therapies that enable cells to circumvent the differentiation block, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia³, but whether 'differentiation therapy' is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood. Here we demonstrate that simultaneous inhibition of the histone demethylase LSD1 (LSD1i) and the WNT pathway antagonist GSK3 kinase⁴ (GSK3i) robustly promotes therapeutic differentiation of established AML cell lines and primary human AML cells, as well as reducing tumour burden and significantly extending survival in a patient-derived xenograft mouse model. Mechanistically, this combination promotes differentiation by activating genes in the type I interferon pathway via inducing expression of transcription factors such as IRF7 (LSD1i) and the co-activator β-catenin (GSK3i), and their selective co-occupancy at targets such as STAT1, which is necessary for combination-induced differentiation. Combination treatment also suppresses the canonical, pro-oncogenic WNT pathway and cell cycle genes. Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML.

Impact Factor

Scopus SNIP

Altmetric

48.500

0.000